Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Biotinylated Human IL-12B&IL-12A Heterodimer Protein, His,Avitag&Flag Tag is produced by co-expression of IL-12B and IL-12A, has a calculated MW of 38.3 kDa (IL-12B) and 23.8 kDa (IL-12A). Subunit IL-12B is fused with a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) and subunit IL-12A is fused with flag tag at the C-terminus. The reducing (R) heterodimer protein migrates as 40-50 kDa (IL12B) and 32-35 kDa (IL12A) respectively due to glyosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human IL-12B&IL-12A Heterodimer, His,Avitag&Flag Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-12B&IL-12A Heterodimer, His,Avitag&Flag Tag (Cat. No. IL2-H8210) with a linear range of 0.039-1.25 μg/mL (QC tested).
Immobilized Biotinylated Human IL-12B&IL-12A Heterodimer Protein, His,Avitag&Flag Tag (Cat. No. IL2-H8210) at 1 μg/mL (100 μL/well)on streptavidin precoated (0.5 μg/well) plate. can bind Monoclonal Anti-Human IL23A&IL12B P40 domain Antibody, Human IgG1 with a linear range of 0.2-1 ng/mL (Routinely tested).
Immobilized Human IL-12 R beta 2, His Tag (Cat. No. ILB-H52H6) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-12B&IL-12A Heterodimer, His,Avitag&Flag Tag (Cat. No. IL2-H8210) with a linear range of 0.003-0.3 μg/mL (Routinely tested).
Price(USD) : $350.00
Price(USD) : $1520.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
Ustekinumab | CNTO-1275; C-340; AVT-04 | Approved | Janssen Global Services Llc | Stelara | Mainland China | Plaque psoriasis | Janssen-Cilag International Nv | 2009-01-15 | Multiple Sclerosis; Dermatitis, Atopic; Plaque psoriasis; Crohn Disease; Uveitis; Common Variable Immunodeficiency; Hidradenitis Suppurativa; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Ichthyosis; Pouchitis; Inflammatory Bowel Diseases; Dermatomyositis; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
EGFR IL12 CART | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Colorectal Neoplasms | Details | |
VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ustekinumab biosimilar (BioFactura) | BFI-751 | BioFactura Australia Pty Ltd | Details | ||
Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) | EN-3348 | Prometic Life Sciences | Details | ||
GX-51 | GX-051 | Pocastem, Genexine Inc | Details | ||
NSC-733972 | M-032; M032-H SV-1; NSC-733972 | University Of Alabama At Birmingham | Details | ||
Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Formycon | Psoriasis | Details |
Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
Apilimod mesilate | STA-5326-mesylate; LAM-002; LAM-002A; STA-5326; AIT-101 | Phase 2 Clinical | Lam, Synta Pharmaceuticals Corp | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Common Variable Immunodeficiency; Crohn Disease; Amyotrophic Lateral Sclerosis | Details |
Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Phase 3 Clinical | Meiji Seika Pharma Co Ltd, Dong-A Pharmaceutical Co Ltd | Psoriasis | Details |
ABOD-2011 | ABOD-2011 | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Solid tumours | Details |
MEDI-9253 | Phase 1 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details | |
MEDI-1191 | MEDI-1191; MEDI1191 | Phase 1 Clinical | Moderna Inc | Solid tumours; Neoplasms | Details |
DF-6002 | DF-6002 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours; Neoplasms | Details |
ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus Inc | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
Ustekinumab biosimilar(CSPC Pharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Liver Neoplasms; Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Cholangiocarcinoma; Carcinoma, Hepatocellular | Details |
INO-9012/Human papillomavirus vaccine | INO-3112; INO-9012/VGX-3100; VGX-3100/INO-9012 | Phase 2 Clinical | University Of Pennsylvania, Astrazeneca Plc, Inovio Pharmaceuticals Inc | Anus Neoplasms; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Papillomavirus Infections; Neoplasms; Carcinoma, Transitional Cell; Vulvar Neoplasms; Oropharyngeal Neoplasms; Penile Neoplasms; Uterine Cervical Neoplasms | Details |
NHS-IL-12 | M-9241; MSB-0010360 | Phase 2 Clinical | National Cancer Institute, Emd Serono Inc, Merck Serono | Vulvar Neoplasms; Sarcoma, Kaposi; Uterine Cervical Neoplasms; Urogenital Neoplasms; Penile Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Head and Neck Neoplasms; Urinary Bladder Neoplasms; Colonic Neoplasms; Papillomavirus Infections; Pancreatic Neoplasms; Carcinoma; Rectal Neoplasms; Vaginal Neoplasms; Anus Neoplasms; Intestinal Neoplasms | Details |
Rocakinogene sifuplasmid | INO-9012 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Carcinoma, Transitional Cell; Carcinoma, Hepatocellular; Precancerous Conditions; Lung Neoplasms; Vulvar Diseases; Squamous Intraepithelial Lesions of the Cervix; Colorectal Neoplasms; Hepatitis C; Breast Neoplasms; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Papillomavirus Infections; Ovarian Neoplasms; Neoplasms, Glandular and Epithelial; Pancreatic Neoplasms; Urogenital Abnormalities; Glioblastoma; Esophageal Neoplasms; Stomach Neoplasms; Hepatitis, Chronic; Head and Neck Neoplasms; HIV Infections; Liver Neoplasms | Details |
Ustekinumab biosimilar(Amgen) | ABP-654 | Phase 3 Clinical | Amgen Inc | Solid tumours; Psoriasis | Details |
T3011 | MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV | Phase 2 Clinical | Immvira Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Mesothelioma; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms | Details |
WTX-124 | WTX-124 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasm Metastasis | Details |
JCXH-211 | JCXH-211 | Phase 1 Clinical | Jiachen Xihai(Hangzhou)Biotechnology Co Ltd | Solid tumours; Skin Neoplasms | Details |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Phase 3 Clinical | Celltrion Inc | Psoriasis | Details |
Veledimex | INXN-1001; AD-1001 | Phase 2 Clinical | Ziopharm Oncology Inc | Glioblastoma; Brain Neoplasms; Breast Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Melanoma | Details |
Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Psoriasis; Plaque psoriasis | Details |
MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms | Details |
Interleukin-12 gene therapy (OncoSec Medical) | pIL-12; DNA IL-12 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Breast Neoplasms; Mycosis Fungoides; Melanoma; Carcinoma, Hepatocellular; Lymphoma, T-Cell, Cutaneous; Lung Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Hepatitis B; Lymphoma, Mantle-Cell; HIV Infections; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Esophageal Neoplasms; Stomach Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
Ustekinumab biosimilar (Bio-Thera ) | BAT-2206 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
This web search service is supported by Google Inc.